Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
March 17, 2026 4:06 PM EDTFollowing the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough
On track to initiate a Phase 2b clinical trial for the treatment of patients with refractory chronic cough in the second quarter of 2026
Company ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, with expected cash runway into 2028
Management to host a conference call and webcast today at 4:30 p.m. ET
NEW HAVEN, Conn., March 17, 2026 (GLOBE NEWSWIRE) --... More
